Jose C. Tapia
@TapiaJC1
Followers
722
Following
4K
Statuses
3K
Medical Oncologist - Urological Cancers. Interested in clinical trials and drug development at @VelindreTrust | ⚽️ fan | Views my own.
Wales, United Kingdom
Joined August 2010
"El que puede cambiar sus pensamientos puede cambiar su destino". Stephen Crane.
0
0
12
Exciting collaborations at @VelindreCS, contributing to two innovative trials: 🔹 Cemiplimab + chemo, followed by maintenance cemiplimab in metastatic penile cancer. 🔹 Transdermal oestradiol (tE2) patches as ADT in ARPI combos for CRPC. #ASCOGU25 #ClinicalTrials
Looking forward to #ASCOGU25
#Prostate: Combos w/ iPARP- and Lu- , EZH2 #Urothelial: Updates, HER-2, FGFR3, and high-risk UTUC #Renal: Updates, UO3B, KIM-1, HIF-2 inh and MET inh. #Testicular: RPLND advanced Seminoma #Penile: IO-chemo for advanced Ca @RickyFrazer1 @mcgranjo777
0
0
3
Looking forward to #ASCOGU25
#Prostate: Combos w/ iPARP- and Lu- , EZH2 #Urothelial: Updates, HER-2, FGFR3, and high-risk UTUC #Renal: Updates, UO3B, KIM-1, HIF-2 inh and MET inh. #Testicular: RPLND advanced Seminoma #Penile: IO-chemo for advanced Ca @RickyFrazer1 @mcgranjo777
1
6
17
RT @VelindreCS: 💚 We were delighted to welcome Cabinet Secretary Jeremy Miles into our Clinical Trials department for World Cancer Day. The…
0
7
0
RT @tompowles1: When to rechallange with PD1 therapy in advanced RCC after progression on/after adjuvant pembro #AUC3 ? Rechallange studies…
0
16
0
Excited to be in Barcelona for the 2nd @GuardConsortium meeting on drug development and regulations for urological cancer. Happy to discuss global disparities in drug approvals for #UrothelialCarcinoma.
1
0
14
RT @declangmurphy: There does seem to be an extraordinary stampede away from Twitter towards Bluesky this past week! This is the first “Twi…
0
2
0
RT @GuardConsortium: ¡Solo queda 1 mes! Apúntate a la II Jornada sobre Acceso a Fármacos en Tumores de la Esfera GU, el 12 de diciembre en…
0
8
0
RT @drenriquegrande: ⚡️Renal Cell Carcinoma Trials Can Inform NICE Guideline on Kidney Cancer #KidneyCancer @TapiaJC1 @RickyFrazer1
@Med…
0
13
0
#SaveTheDate 12-Dic-2024 Una reunión para discutir los retos y las oportunidades en el acceso a fármacos para tumores urológicos. Discutiremos los datos presentados en #ESMO24 sobre las diferencias entre EU y Norte América👇🏼🔗 @_SEOM @GuardConsortium
El 12-dic-2024, en Barcelona, acompáñanos en la II Jornada de Acceso a Fármacos en tumores de la esfera GU, organizada por @GuardConsortium. Discusión abierta en un foro que invita a todos los agentes implicados en este proceso. Más información en
0
3
7
@RickyFrazer1 @MedscapeUK @VelindreCC @Medscape You are so kind Ricky. True is that you are an incredible mentor and nothing would have been possible without your support. Many thanks!
0
0
0
@mjuanfi81 @ChrisSweens1 Liked. @RickyFrazer1 this is your if if if if if if if if …for IO in prostate. 😂
0
0
1
RT @RowanneSeadon: Excited to present my poster on #QualityOfLife data in trials data for #RCC at @myESMO alongside @TapiaJC1 this weekend!…
0
2
0
Very proud of @RowanneSeadon . CNS from @VelindreCC who presented her poster about #QualityOfLife data in trials for #RCC at #ESMO24. Outstanding perspective from the CNS point of view 👌🏼 FYI @crisbergerot @tompowles1
0
7
16
Practice changing #NIAGARA trial in NAC #MIBC. Another crystal clear trial from Prof Powles. Early (2y) OS and EFS benefit from moving IO forward in UC. Also, ⬆️ pCR. Reaffirms that we must avoid PDL1 selection. Future? ADC would be better than CIS.
Perioperative durvalumab + neoadjuvant chemo & cystectomy in operable bladder cancer significantly delays (HR 0.68) event free survival and a 25% reduction in the risk of death. 10% ⬆️ pCR. It’s the 1st time immune therapy has an OS benefit in muscle invasive UC #ESM024 @NEJM
0
0
3
Outstanding effort. PEACE-3 reaffirmed that Ra223 + Bone protecting are relevant in CRPC. OS +ve but with caveats. Data on subsequent Rx in the control arm?. Confirms rPFS as a surrogate endpoint? Won’t change current landscape of PCa treatment #ESMO24
Outstanding talk from @Silke_Gillessen elegantly presenting PEACE-3 phase 3 trials first results. Adding 6 cycles of Ra223 to enzalutamide as first-line therapy for mCRPC showed significant rPFS improvement + significant OS benefit #ESMO24 @myESMO
@OncoAlert @urotoday
0
2
8
Continue with IO beyond PD is not an optimal strategy anymore. Are we convinced? @RickyFrazer1. Some argued about ⬆️ Tivo dosage in the control arm. My feeling is that long-term IO’s benefits remain despite stopping it. Combos could be disruptive in latter lines. #ESMO24
Tivozanib +/- nivolumab in IO pretreated M1 renal cancer showed retreatment with IO makes absolutely no difference. This is on top of CONTACT3 which showed the same thing.We need to stop retreating with IO.These data apply in the post adjuvant setting too without data #ESMO2024
1
0
2